At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 enrolled
Drug / intervention
Macimorelin +1 moredrug
Likely dose
Macimorelin 1 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia
In Brief
A Phase 2 clinical trial evaluating Macimorelin and Placebo for Cancer Cachexia. Completed, enrolled 15 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of repeated oral administration of macimorelin at different doses daily for 1 week for the treatment of cancer cachexia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer Cachexia
CountriesUnited States
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2012
First PostedJun 2012
Primary CompletionJul 2020
Study CompletionDec 2021
TodayJul 2026
First PostedJun 8, 2012
Enrollment StartMay 1, 2012
Primary CompletionJul 1, 2020
Study CompletionDec 1, 2021
TodayJul 2, 2026
Enrollment to primary: 8.2 yearsPosted 14.1 years ago
Interventions
Macimorelindrug
Subjects will receive macimorelin (1 mg/kg) and matching placebo (Powerade®) daily for 7 days.
Placebodrug
placebo (Powerade®) daily for 7 days.